ECSP077397A - Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad - Google Patents

Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad

Info

Publication number
ECSP077397A
ECSP077397A EC2007007397A ECSP077397A ECSP077397A EC SP077397 A ECSP077397 A EC SP077397A EC 2007007397 A EC2007007397 A EC 2007007397A EC SP077397 A ECSP077397 A EC SP077397A EC SP077397 A ECSP077397 A EC SP077397A
Authority
EC
Ecuador
Prior art keywords
carbonilamine
bifenil
preparation
acid derivatives
obesity treatment
Prior art date
Application number
EC2007007397A
Other languages
English (en)
Inventor
Derek B Lowe
Tatiana E Shelekhin
Roger A Smith
Ann-Marie Campbell
Philip Coish
Stephen O'connor
Roger B Clark
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ECSP077397A publication Critical patent/ECSP077397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a ciertos compuestos de ácido bifenil-4-il carbonilamino, composiciones y métodos para tratar o prevenir obesidad y enfermedades relacionadas.
EC2007007397A 2004-10-15 2007-04-13 Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad ECSP077397A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61897504P 2004-10-15 2004-10-15

Publications (1)

Publication Number Publication Date
ECSP077397A true ECSP077397A (es) 2007-05-30

Family

ID=36203612

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007397A ECSP077397A (es) 2004-10-15 2007-04-13 Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad

Country Status (21)

Country Link
US (2) US7759376B2 (es)
EP (1) EP1805156B1 (es)
JP (1) JP2008516978A (es)
KR (1) KR20070063546A (es)
CN (1) CN101087769A (es)
AT (1) ATE492542T1 (es)
AU (1) AU2005295453A1 (es)
BR (1) BRPI0516483A (es)
CA (1) CA2583784A1 (es)
CR (1) CR9034A (es)
DE (1) DE602005025517D1 (es)
EA (1) EA200700851A1 (es)
EC (1) ECSP077397A (es)
ES (1) ES2357015T3 (es)
IL (1) IL182218A0 (es)
MA (1) MA28935B1 (es)
MX (1) MX2007004217A (es)
NO (1) NO20072461L (es)
TN (1) TNSN07111A1 (es)
WO (1) WO2006044775A2 (es)
ZA (1) ZA200703002B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
JP2009520786A (ja) 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
NZ572586A (en) 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
KR20090010092A (ko) 2006-05-30 2009-01-28 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP5662803B2 (ja) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０
LT2303270T (lt) 2008-05-05 2017-09-11 Sanofi Acilamino-pakeistieji sulieti ciklopentankarboksirūgšties dariniai ir jų panaudojimas kaip vaistų
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
US20100168079A1 (en) * 2008-12-23 2010-07-01 Daniela Angst Biaryl Benzylamine Derivatives
EP2389366A1 (en) * 2009-01-23 2011-11-30 Msd K.K. Benzodiazepin-2-on derivatives
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
AR079022A1 (es) * 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
NZ599855A (en) 2009-11-05 2014-06-27 Piramal Entpr Ltd Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity
MX341841B (es) 2009-12-16 2016-09-05 Pola Chem Ind Inc Agente de prevencion o mejoramiento para la pigmentacion.
US9061012B2 (en) 2010-03-30 2015-06-23 Novartis Ag Uses of DGAT1 inhibitors
KR101392334B1 (ko) 2011-05-03 2014-05-12 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2015295376C1 (en) * 2014-08-01 2020-07-16 Bayer Pharma Aktiengesellschaft Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
CN105646510A (zh) * 2014-12-02 2016-06-08 重庆宁牧生态农业有限公司 一种用作抗肥胖剂的化合物
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
AU2020291464A1 (en) * 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) * 2020-10-19 2021-02-09 济南大学 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) * 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Also Published As

Publication number Publication date
JP2008516978A (ja) 2008-05-22
ZA200703002B (en) 2008-08-27
EP1805156A2 (en) 2007-07-11
WO2006044775A3 (en) 2006-06-15
MA28935B1 (fr) 2007-10-01
CN101087769A (zh) 2007-12-12
EP1805156A4 (en) 2009-06-10
NO20072461L (no) 2007-07-03
IL182218A0 (en) 2007-09-20
EA200700851A1 (ru) 2007-12-28
BRPI0516483A (pt) 2008-09-02
TNSN07111A1 (en) 2008-06-02
MX2007004217A (es) 2007-06-11
ES2357015T3 (es) 2011-04-15
ATE492542T1 (de) 2011-01-15
EP1805156B1 (en) 2010-12-22
CA2583784A1 (en) 2006-04-27
DE602005025517D1 (de) 2011-02-03
KR20070063546A (ko) 2007-06-19
CR9034A (es) 2008-11-18
WO2006044775A2 (en) 2006-04-27
US7759376B2 (en) 2010-07-20
US20070265298A1 (en) 2007-11-15
AU2005295453A1 (en) 2006-04-27
US20110118302A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
CR9034A (es) Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
SV2006002187A (es) Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)
EA201000050A1 (ru) Замещенные бициклолактамные соединения
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY28734A1 (es) Compuestos de quinolina sustituidos
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
UY29161A1 (es) Nuevos heterociclos
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
NI200700323A (es) 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
DOP2004000900A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
CU20080120A7 (es) Derivados de pirimidinil aril urea e inhibidores fgf
DOP2005000015A (es) Compuestos de quinolina sustituidos